

### **Amendments to the Specification**

**Page 1, immediately after the title, please insert:**

This application is a continuation of Serial No. 09/937,296 filed November 14, 2001, which is a U.S. national stage of International Application No. PCT/GB00/01740 filed May 5, 2000.

**Page 4, lines 16 to 22, please rewrite the paragraph as follows:**

One particularly preferred modification is the addition of a fluorescent label to the enzyme, typically via a cysteine residue. If the wild-type protein lacks a suitable cysteine residue (*e.g.* the NDPK of *Myxococcus xanthus* (SEQ ID NO: 1)), this can easily be introduced by mutagenesis [*e.g.* 19]. A suitable position for mutation can easily be determined by the skilled person, whilst ensuring that the mutation does not disrupt the enzymatic activity [*e.g.* 20]. At any given amino acid residue, particular labels may give better results than others. Suitable combinations of label and residue can be determined by routine experimentation.

**Page 8, lines 14-16, please rewrite the paragraph as follows:**

Various mutant proteins containing cysteine residues were prepared, including D112C (*i.e.* Asp-112 was mutated to Cys (SEQ ID NO: 2)) and D62C. Positions for mutation were typically chosen on the basis of their proximity to the nucleotide-binding cleft seen in the crystal structure [16].

**Amendments to the Sequence Listing**

Please transfer the paper and computer readable copies of the Sequence Listing from the parent application to the present application.